Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva

IPO Edge hosted a fireside chat with Jupiter Neurosciences, Inc. (Nasdaq: JUNS) Chairman, Chief Executive Officer and Co-founder Christer Rosén and Alison Silva, President and Chief Operations Officer, moderated by IPO Edge Editor-in-Chief John Jannarone in a video session lasting approximately 30 minutes.

The company recently signed a definitive licensing agreement with PharmAla Biotech for perpetual exclusive U.S. rights to ALA-002, a patented formulation of MDMA. The deal, valued at up to $100 million including milestones, transforms Jupiter into a dual clinical-stage CNS company, adding ALA-002 to its existing Phase II Parkinson's disease program.

The recent acquisition in the psychedelics field of ALA-002, a patented, non-racemic MDXX molecule for which the company now owns the exclusive U.S. license.

Status of the company's Phase 2 trial in Parkinson's Disease

The primary indication for ALA-002 and where it might be applied, its addressable market size, and its potential revenue in comparison to the cost of the acquisition

The U.S. government position regarding the psychedelics field

Milestones investors should be focused on across the company's portfolio, including JOTROL

Mr. Rosén is co-founder, Chief Executive Officer and Chairman of the Board of Directors of Jupiter Neurosciences, Inc. since January 1, 2016. Mr. Rosén is a serial entrepreneur and has started several businesses in various industries. From 1997 through May 2015, Mr. Rosén founded and served as the Chief Executive Officer and Chairman of EffRx Pharmaceuticals. At EffRx Mr. Rosén, together with an experiences pharmaceutical team, invented, developed and received FDA and EU approvals of a drug treating osteoporosis, Binosto. Binosto is distributed in several parts of the world and gave Mr. Rosén a full insight in all the aspects of pharmaceutical development, regulatory paths and worldwide distribution. EffRx was acquired in 2023 by Abiogen SA.

Mr. Rosén is a graduate of Malmo Trade Schools/Lund University, Sweden, with a degree in Computer Sciences in 1971.

Alison D. Silva is the President and Chief Operating Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). She is also the President, Chief Executive Officer and a Director of Cotinga Pharmaceuticals Inc., formerly Critical Outcome Technologies, Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer at Synlogic, Inc. where she lead the regulatory strategy, drug development, and operational aspects of the company's focus on the discovery and development of engineered therapeutic probiotics. Alison is also a co‐founder of The Orphan Group, a specialty consulting company focused on assisting companies with developing and implementing their orphan drug strategy and product lifecycle management.

Alison previously held the position of Chief Operating Officer at SLA Pharma, a GI‐oncology focused biotech company, where she was responsible for heading up U.S. corporate and clinical operations for their pipeline of orphan drug candidates. Prior to joining SLA Pharma, Alison was Vice President of Drug Development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010, where she held the same role since 2007. Alison began her career in drug development in clinical operations with various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts. Alison obtained her undergraduate degree from Clark University and her graduate degree from the University of Massachusetts Medical Center.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL — a proprietary, enhanced bioavailability resveratrol formulation — is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia, a consumer longevity supplement.

The Company has recently entered into a term sheet to acquire ALA-002 from PharmAla Biotech, a next-generation, patented psychedelic NCE. The closing of this transaction would further strengthen the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy.

For more information, please visit www.jupiterneurosciences.com .

Sinergia Empresarial continuará el seguimiento de esta información sobre psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.